Akero Therapeutics Inc
(AKRO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -252,060 | -151,759 | -112,033 | -100,777 | -79,207 |
| Depreciation Amortization | -12,493 | -9,077 | 235 | 1,107 | 100 |
| Accounts payable and accrued liabilities | 2,008 | -645 | 968 | 3,273 | 2,481 |
| Other Working Capital | 2,998 | -6,670 | -4,459 | 9,727 | 2,085 |
| Other Operating Activity | 29,440 | 22,784 | 22,772 | 6,989 | 3,737 |
| Operating Cash Flow | $-230,107 | $-145,367 | $-92,517 | $-79,681 | $-70,804 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -108,709 | -223,623 | -63,825 | 42,280 | -9,613 |
| PPE Investments | N/A | N/A | N/A | N/A | -148 |
| Other Investing Activity | -999 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | $-109,708 | $-223,623 | $-63,825 | $42,280 | $-9,761 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 10,000 | 15,000 | 10,000 | N/A | N/A |
| Common Stock Issued | 436,690 | 339,092 | 246,496 | 1,123 | 203,055 |
| Other Financing Activity | -844 | -776 | -864 | -521 | 52 |
| Financing Cash Flow | $445,846 | $353,316 | $255,632 | $602 | $203,107 |
| Beginning Cash Position | 234,207 | 249,881 | 150,591 | 187,390 | 64,848 |
| End Cash Position | 340,238 | 234,207 | 249,881 | 150,591 | 187,390 |
| Net Cash Flow | $106,031 | $-15,674 | $99,290 | $-36,799 | $122,542 |
| Free Cash Flow | |||||
| Operating Cash Flow | -230,107 | -145,367 | -92,517 | -79,681 | -70,804 |
| Capital Expenditure | N/A | N/A | N/A | N/A | -148 |
| Free Cash Flow | -230,107 | -145,367 | -92,517 | -79,681 | -70,952 |